BOLT BIOTHERAP. DL-00001
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform th… Read more
Market Cap & Net Worth: BOLT BIOTHERAP. DL-00001 (6LP)
BOLT BIOTHERAP. DL-00001 (F:6LP) has a market capitalization of $10.19 Million (€9.93 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #37386 globally and #4807 in its home market, demonstrating a 1884.67% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BOLT BIOTHERAP. DL-00001's stock price €5.18 by its total outstanding shares 1916980 (1.92 Million).
BOLT BIOTHERAP. DL-00001 Market Cap History: 2021 to 2025
BOLT BIOTHERAP. DL-00001's market capitalization history from 2021 to 2025. Data shows change from $7.91 Million to $10.19 Million (-31.70% CAGR).
BOLT BIOTHERAP. DL-00001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BOLT BIOTHERAP. DL-00001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6LP by Market Capitalization
Companies near BOLT BIOTHERAP. DL-00001 in the global market cap rankings as of March 19, 2026.
Key companies related to BOLT BIOTHERAP. DL-00001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
BOLT BIOTHERAP. DL-00001 Historical Marketcap From 2021 to 2025
Between 2021 and today, BOLT BIOTHERAP. DL-00001's market cap moved from $7.91 Million to $ 10.19 Million, with a yearly change of -31.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €10.19 Million | +970.25% |
| 2024 | €952.38K | -49.00% |
| 2023 | €1.87 Million | -22.21% |
| 2022 | €2.40 Million | -69.65% |
| 2021 | €7.91 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of BOLT BIOTHERAP. DL-00001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.19 Million USD |
| MoneyControl | $10.19 Million USD |
| MarketWatch | $10.19 Million USD |
| marketcap.company | $10.19 Million USD |
| Reuters | $10.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.